Apixaban Intermediate CAS 503615-03-0 3-Morpholino-1- (4-Nitrophenyl) -5,6-Dihydropyridin-2 (1H) -ɗaya Tsabta ≥99.0% (HPLC)

3-Morpholino-1- (4-Nitrophenyl) -5,6-Dihydropyridin-2 (1H) -daya (CAS: 503615-03-0) shine matsakaici don kira na Apixaban (CAS: 503612-47-3) .
Apixaban sabon nau'in mai hana factor Xa factor ne tare da Bristol-Myers Squibb da Pfizer suka haɓaka.Sunan kasuwanci shine Eratol, wanda shine sabon nau'in maganin ciwon ciki na baka.Ta hanyar hana wani muhimmin coagulation factor Xa, Apixaban zai iya hana thrombin samar da thrombosis.
A ranar 26 ga Afrilu, 2007, Bristol-Myers Squibb ya haɗa hannu tare da Pfizer don sanar da haɗin gwiwa a cikin haɓaka sabon maganin maganin jijiyoyi na baki Apixaban mallakar Bristol-Myers Squibb a matsayin ingantaccen madadin warfarin.Bisa yarjejeniyar haɗin gwiwa, Pfizer zai biya bashin dalar Amurka biliyan 0.25 ga Bristol-Myers Squibb don ɗaukar 60% na jimlar ci gaba na ci gaban maganin ƙwanƙwasa Apixaban (wanda za a aiwatar daga Janairu 1, 2007), yayin da Bristol-Myers Squibb zai ɗauki sauran 40%, don haka samun haƙƙin haɓakawa da sayar da magani tare.
A cikin watan Mayu 2011, Apixaban shine farkon wanda ya amince da rigakafin thrombosis na jijiyoyi a cikin manya marasa lafiya da ke fuskantar zaɓaɓɓen hip ko gwiwa a cikin ƙasashen 27 EU, Iceland da Norway.
A ranar 20 ga Nuwamba, 2012, Hukumar Tarayyar Turai ta amince da Ererto (Apixaban) don rigakafin bugun jini da bugun jini a cikin tsofaffi marasa lafiya tare da ƙananan ƙwayar ƙwayar cuta (NVAF) tare da ɗaya ko fiye da abubuwan haɗari.Bayan haka, Hukumar Abinci da Magunguna ta Kanada, Japan, da FDA ta Amurka sun amince da Ererto (Apixaban) don rigakafin bugun jini da bugun jini a cikin manya marasa lafiya waɗanda ba su da fibrillation na valvular (NVAF) tare da abubuwan haɗari ɗaya ko fiye.
A ranar 12 ga Afrilu, 2013, an ba da sanarwar cewa za a jera sabon magani na Eloto (ELIQUIS) (apixaban) tare da haɗin gwiwar Bristol-Myers Squibb da Pfizer a cikin kasar Sin.Ererto wani labari ne na baka na Xa inhibitor don rigakafin thromboembolism venous (VTE) a cikin manya marasa lafiya da ke fuskantar zaɓen hip ko gwiwa.Jerin sa yana ba da sabon zaɓi mai aminci kuma mai inganci don maganin ƙwanƙwasawa na asibiti bayan tiyatar orthopedic, kuma yana kawo labari mai daɗi ga majinyatan Sinawa waɗanda ke fuskantar maye gurbin hip/ gwiwa.Nazarin asibiti sun tabbatar da cewa idan aka kwatanta da 40mg enoxaparin sau ɗaya a rana, sau 2 a rana gudanarwar baki na Eratol (Apixaban) 2.5mg ya fi tasiri don hana thromboembolism na jini bayan tiyatar maye gurbin hip ko gwiwa, kuma baya ƙara haɗarin zubar jini.